08/11/2024  17:27:08 Chg. +0.40 Volume Bid17:30:00 Demandez à17:30:00 Capitalisation boursière Dividende Y. Rapport P/E
31.55EUR +1.28% 3,525
Chiffrre d'affaires: 56,696.50
-Bid taille: - -Ask la taille: - 1.66 Mrd.EUR 2.85% 26.59

Description de l'entreprise

Dermapharm is a leading manufacturer of patent-free branded pharmaceuticals for selected markets in Germany. Founded in 1991, the company is based in Grünwald near Munich and has its main manufacturing facility in Brehna near Leipzig. The company’s integrated business model comprises inhouse development, in-house production and distribution of pharmaceuticals and other healthcare products for specifically targeted markets by a medical and pharmaceutical sales force. Dermapharm holds approximately 900 marketing authorizations (Arzneimittelzulassungen) for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. This assortment makes the company unique. In addition to Germany, the company’s core markets also include Austria and Switzerland. The company plans to further expand its international presence. Dermapharm’s business model also includes a parallel import business, which operates under the “axicorp” brand.
 

Conseil d'administration & Conseil de surveillance

PDG
Dr. Hans-Georg Feldmeier
Conseil d'administration
Dr. Andreas Eberhorn, Christof Dreibholz
Conseil de surveillance
Wilhelm Beier, Dr. Erwin Kern, Lothar Lanz
 

Données de l'entreprise

Nom: Dermapharm Holding SE
Adresse: Lil-Dagover-Ring 7,D-82031 Grünwald
Téléphone: +49-89-64186-0
Fax: +49-89-64186-130
Courriel: -
Internet: ir.dermapharm.de/index.php
Industrie: Healthcare
Secteur: Pharmaceutical Industry
Sous-secteur: Pharmaceuticals
Fin de l'exercice financier: 31/12
Flotte libre: -
IPO date: 09/02/2018

Relations avec les investisseurs

Nom: Britta Hamberger
Téléphone IR: +49-89-64186-233
IR-Fax: +49-89-64186-165
E-mail IR: ir@dermapharm.com

Calendrier de l'entreprise

CW 46 | 14/11/2024 Interim Report 3rd Quarter/9 Months
 

Principaux actionnaires

Themis Beteiligungs-AG
 
68.50%
FreeFloat
 
31.50%